Department of Breast Oncology, Gunma Prefectural Cancer Center, 617-1 Takabayashi-nishi cho, Ota, Gunma, 373-8550, Japan.
Breast Cancer. 2013 Jan;20(1):75-82. doi: 10.1007/s12282-011-0311-4. Epub 2011 Dec 28.
Primary systemic therapy (PST; such as chemotherapy) has been approved as the standard therapy. Breast-conserving surgery is involved in 60-70% of breast cancer operations, and cancer can spread in the period between the initial treatment and preoperative chemotherapy. To reduce the residual tumor in persistent disease of breast tissue, determining the margin including normal tissue when removing the tumor is very difficult. With the development of the color Doppler method, contrast-enhanced ultrasonography (CEUS) allows visualization of the tumor bloodstream. The availability and efficacy of CEUS for setting the resection margin in breast-conserving surgery were examined and compared with MRI imaging as tools for making decisions for breast-conserving surgery.
One hundred seventy patients underwent breast cancer operations: 59 were PST(+) and 111 PST(-). Imaging studies, ultrasonography and MRI, to measure the size of the tumor were performed twice, before and after chemotherapy, for PST patients. This was carried out not only to measure the residual tumor size after PST, but also to detect whether pathologically complete response (pCR) had been achieved or not. Fifty-nine patients received CEUS after PST, and we determined the precision of CEUS and conventional US.
The sensitivity of CEUS for pCR was 80.0% (95% CI 0.571-0.88), specificity 98.0% (95% CI 0.933-0.996), positive predictive value 88.9% (95% CI 0.635-0.978) and negative predictive value 96.0% (95% CI 0.914-0.976). The difference between the pathological examination and ultrasonography, conventional ultrasonography and CEUS was -4.455 ± 2.02 and 2.582 ± 2.298 cm (95% CI -13.11 to -0.96, p = 0.0235); CEUS was near the diameter of the actual pathological examination.
Contrast-enhanced ultrasonography is suitable for the preoperative examination, especially after PST, to determine the resection margin before breast-conserving surgery and detects pCR, which can help to avoid surgical procedures in the future.
新辅助化疗(PST;如化疗)已被批准为标准治疗方法。保乳手术占乳腺癌手术的 60-70%,癌症可以在初始治疗和术前化疗之间的时期内扩散。为了减少乳腺组织中持续性疾病的残留肿瘤,在切除肿瘤时确定包括正常组织的切缘非常困难。随着彩色多普勒方法的发展,对比增强超声(CEUS)可使肿瘤血流可视化。检查并比较了 CEUS 作为保乳手术决策工具在保乳手术中设定切缘的有效性,并与 MRI 成像进行了比较。
170 名患者接受了乳腺癌手术:59 名患者接受了 PST(+)治疗,111 名患者接受了 PST(-)治疗。对 PST 患者进行了两次影像学检查、超声和 MRI,以测量肿瘤的大小。这不仅是为了测量 PST 后残留肿瘤的大小,也是为了检测是否达到病理完全缓解(pCR)。59 名患者在 PST 后接受了 CEUS,我们确定了 CEUS 和常规 US 的精度。
CEUS 对 pCR 的灵敏度为 80.0%(95%CI 0.571-0.88),特异性 98.0%(95%CI 0.933-0.996),阳性预测值 88.9%(95%CI 0.635-0.978),阴性预测值 96.0%(95%CI 0.914-0.976)。病理检查与超声、常规超声与 CEUS 的差值分别为-4.455±2.02 和 2.582±2.298cm(95%CI-13.11 至-0.96,p=0.0235);CEUS 接近实际病理检查的直径。
CEUS 适用于保乳手术前的术前检查,尤其是在 PST 后,以确定保乳手术前的切缘,并检测 pCR,这有助于避免未来的手术程序。